Laxative tablets recalled due to labeling error

recalls Shutterstock 347x210 Laxative tablets recalled due to labeling errorMagno-Humphries Laboratories Inc., is recalling one lot of Basic Drugs Brand Senna Laxative tablets because one bottle labeled as Senna Laxative actually contained Basic Drugs Brand Naproxen Sodium, a pain reliever known as a nonsteroidial anti-inflammatory drug (NSAID).

Unintentional consumption of naproxen could result in deadly side effects in patients with underlying illnesses, including allergies, cardiac, gastrointestinal, hepatic, and renal conditions, as well as those who have recently undergone cardiac bypass graft surgeries. Inadvertent overdose could also occur in patients who have taken another NSAID at the same time, increasing the risk for NSAID-associated side effects, which include heart attack, stroke, congestive heart failure, renal toxicity, bleeding, ulceration, or perforation of the stomach or the intestines.

Those most at risk for adverse events related to this mislabeling issue are children, pregnant women, nursing mothers and surgical patients. To date, Magno-Humphries Laborities has not received any reports of adverse events related to these recalled products.

The recall affects Basic Drugs Brand Senna Laxative tablets, 8.6mg Sennosides, used to treat constipation. The product is packaged in 100-count bottles with an outer neck seal and a child resistant cap, and is marked with the Lot#3523000, EXP: 01/19 printed on the bottom. The tablets inside the bottles may actually contain Basic Drugs Brand Naproxen Sodium 220mg. Affected bottles were distributed nationwide to secondary distributors, retail pharmacies, and via the internet.

Consumers with affected bottles of Basic Drugs Brand Senna Laxative tablets should contact their doctors if they experience any problems that may be related to taking or using this product. Questions regarding this recall should be directed to Magno-Humphries Laboratories at 503-684-5464.

Any adverse events related to use of affected laxatives should be reported to the Food and Drug Administration (FDA) MedWatch Adverse Event Reporting Program at

Source: FDA Recall Notice